Bristol Myers Squibb AI Adoption Tracker
Last updated: April 30, 2026
Overview
Bristol Myers Squibb (BMS) has positioned itself as a leader in pharmaceutical AI adoption with a comprehensive strategy spanning drug discovery, clinical trials, and commercialization. The company follows a "predict first" approach, using AI to evaluate molecular properties before synthesis, with all small molecule programs now employing AI for efficacy prediction—a dramatic increase from just 5% in 2021[1]. BMS has invested over $130 million in AI-enabled capabilities across marketing and commercial functions, establishing a generative AI hub called "Mosaic" in Mumbai through a partnership with Accenture[2]. The company has implemented more than 30 generative AI solutions across R&D, product development, and commercialization, including "Workbench," a clinical trial accelerator that has reduced trial execution times by months[3].
AI Maturity Index
Radar Comparison
Peer Comparison: Bristol Myers Squibb vs healthcare
Based on 66 companies in sector
| Dimension | Bristol Myers Squibb | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 4.0 | 3.7 | +0.3 |
| Proficiency | 4.0 | 3.5 | +0.5 |
| Impact | 4.0 | 3.6 | +0.4 |
| Overall | 4.0 | 3.6 | +0.4 |
Key Metrics
AI Initiatives
Mosaic AI Content Hub
December 2025
Generative AI-powered content hub for accelerated commercialization
End-to-end AI-enabled platform that identifies physician educational needs in real-time and enables rapid creation of patient-centric content. Successfully piloted across three US brands (Reblozyl, Camzyos, Cobenfy) with global expansion planned.
Predict First AI Strategy
July 2025
AI-driven approach to drug discovery that validates molecules before laboratory synthesis
All of BMS's small molecule programs now use AI to evaluate properties like efficacy prior to synthesis, up from just 5% in 2021. Applied to nearly half of large molecule experiments as well.
Workbench Clinical Trial Platform
2025
AI-driven clinical trial accelerator with real-time operational insights
Adopted by over 30 top priority clinical trial teams, with users surging from under 100 to nearly 900 in 3 months. Provides complete visibility into key metrics and generates actionable recommendations.
Frequently Asked Questions
BMS uses AI to evaluate molecular properties like efficacy and safety before synthesis in the laboratory, allowing them to focus resources on the most promising candidates and avoid costly failures.
BMS has committed over $130 million specifically to AI initiatives and AI-enabled capabilities across marketing and commercialization functions.
Mosaic is BMS's generative AI-powered content hub located in Mumbai, India, designed to identify physician educational needs in real-time and rapidly create personalized medical content.
BMS uses Workbench, an AI-driven clinical trial accelerator developed with Accenture that provides real-time operational data and has accelerated clinical trials by months.
BMS has strategic partnerships with Accenture, Exscientia, Immunai, AI Proteins, and Insitro, covering drug discovery, clinical trials, immune system analysis, and commercialization with combined deal values exceeding $3 billion.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Custom ChatGPT | Internal/BMS | Private, secure AI solution trained on BMS data for document summarization, project planning, and data extraction |
| AMICA-OS | Immunai | AI operating system for analyzing high-dimensional immune data from clinical studies |
| ChemML | Insitro | End-to-end drug design platform for small molecule discovery and optimization |
| Workbench | BMS/Accenture | Clinical trial accelerator providing AI-driven insights and real-time operational data |
Sources
How Bristol Myers Squibb uses AI to validate drugs before they're even in the lab
Bristol Myers Squibb Launches Mosaic: Signals a New Era for Tech-Accelerated Patient Care
Bristol Myers Squibb accelerates drug development with generative AI
Immunai, BMS Join Forces to Advance Clinical Development
AI Proteins lands $400M drug discovery deal with Bristol Myers
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.